News | June 26, 2014

Advanced Alumina Ceramic Finds Niche in Oncology Equipment

June 25, 2014 — Thanks to its excellent dielectric properties and a reliable surface finish, a high-quality alumina ceramic from Morgan Advanced Materials is now being successfully used in radiotherapy equipment for oncology treatment.

Deranox 970 is a high-density, non-porous and vacuum-tight material with a 97 percent aluminium oxide content, which provides excellent electrical insulation. It is frequently used in high-vacuum systems, in laser and microscope applications and as an insulator in medical and scientific equipment, and has now been specified as the sealing element for RF windows in radiotherapy equipment.

Acting as a mechanical seal at either end of the vacuum chamber through which electron beams pass in the radiotherapy process, RF windows maintain the integrity of the vacuum, allowing electrons to pass through while preventing both ingress of contaminants and vacuum leakage.

Yannick Galais from Morgan explained: “While most solutions for RF windows contain around 97 percent alumina, it is the remaining 3 percent that makes all the difference in dielectric performance. The alumina ceramic formulation of Deranox 970 provides a high dielectric constant — 9.85 and 9.84 at 2.8GHz and 2.9GHz respectively — and low loss tangent — 0.00109 and 0.00110 at 2.8GHz and 2.9GHz respectively. Externally tested and verified by an independent and fully accredited testing house to an internationally recognized standard, ASTM D2520, these properties contribute to excellent stability at high frequencies.

“Our sophisticated powder manufacturing processes provide excellent repeatability from batch to batch, between batches, which is a key parameter in tuning the nominal wavelength and beam frequency, which will ultimately determine the performance of the of the radiotherapy machine. Our precision machining capabilities guarantee a consistent surface finish and flatness preventing RF reflectance and thus eliminating heat and leakage over time. Providing an impurity-free surface finish also improves the performance of the radiotherapy machinery by removing any potential for oxidation on the RF window,” Galais said.

Using advanced simulation techniques and extensive modeling, Deranox 970 has been comprehensively tested for radiotherapy applications prior to the prototype stage to ensure its suitability — followed by in-depth real-life testing to ensure optimum performance within a very tight tolerance range. Developed alongside Deranox 970 for radiotherapy equipment, Morgan has also introduced a tailored moly-manganese metalizing ink to facilitate the bonding process when the RF window is brazed to the body of the machine, creating the optimum seal and safeguarding the vacuum. As each RF window is individually designed for specific machinery, Morgan’s inks are custom formulated for each material grade. In addition to the ceramic, Morgan is able to supply the complete RF window sub-assembly including mounting flanges. Innovative design features allow Morgan to offer ceramic RF windows brazed inside the oxygen free copper (OFC) vacuum chamber.

Galais continued, “RF windows made of Deranox 970 will last the lifetime of the radiotherapy equipment — generally 20 years plus. Within the highly time-sensitive oncology treatment pathway, disruption to therapy machinery is simply not an option and failure of an RF window will often require full replacement of the radiotherapy machine, at enormous cost to the hospital trust and causing unacceptable delays for patients. The purity of our Deranox 970 material, coupled with its reliable dielectric properties and Morgan’s extensive modeling and test processes, ensure a high-quality RF window solution with long-lasting performance.”

For more information: www.morganadvancedmaterials.com

Related Content

Sponsored Content | Videos | Information Technology | August 22, 2017
Melissa Martin, MS, president of the American Association of Physicists in Medicine (AAPM), discusses her vision of t
Sponsored Content | Videos | Proton Therapy | August 21, 2017
Mark Pankuch, Ph.D., director of medical physics at the Northwestern Medicine Chicago Proton Center, discusses the cl
Summit Cancer Center-Boise Treats First Cancer Patients With Accuray Radixact System
News | Image Guided Radiation Therapy (IGRT) | August 21, 2017
Accuray Inc. and the Summit Cancer Center-Boise announced that the center is now treating patients with the Radixact...
MedStar Georgetown Proton Center Selects RayStation for Treatment Planning
News | Treatment Planning | August 17, 2017
August 17, 2017 — The proton center at MedStar Georgetown University Hospital will utilize RayStation for planning on
DOSIsoft Releases ISOgray Proton Therapy Treatment Planning System
Technology | Treatment Planning | August 15, 2017
DOSIsoft SA announced the official release, with CE marking, of ISOgray Treatment Planning System (TPS) release 4.3 for...
First Radixact Results Presented at AAPM 2017
News | Radiation Therapy | August 10, 2017
Accuray Inc. announced that the first studies validating the benefits of the Radixact System were presented at the 59th...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
Aktina’s interchangeable cones are lightweight and extremely accurate
News | Radiation Therapy | August 02, 2017
Aktina Medical announced a collaboration with Philips Medical Systems and Elekta Instruments for SRS interlocking at...
News | Image Guided Radiation Therapy (IGRT) | July 31, 2017
Elekta’s magnetic resonance radiation therapy (MR/RT) system will be the subject of 21 abstracts at the 59th American...
Overlay Init